Relmada Q2 2026 earnings: R&D spending rises ahead of planned IND filings

Relmada Therapeutics (Nasdaq: RLMD) reported a Q2 2026 GAAP loss of $0.11 per basic and diluted share, compared with $0.30 a year earlier; the clinical-stage company did not report revenue. Net loss nevertheless widened to $12.9 million as research and development spending increased, while cash, cash equivalents and short-term investments reached $217.7 million.

Core financial results

R&D expense nearly tripled to $8.4 million, primarily because of higher study costs for NDV-01 and sepranolone and increased manufacturing and drug-storage costs. Lower employee compensation provided only a partial offset.

G&A expense declined, but that reduction was not enough to offset the higher development spending. Increased interest and investment income helped narrow the difference between the $15.0 million operating loss and the $12.9 million net loss.

Pipeline progress and operating priorities

NDV-01 manufacturing and chemistry, manufacturing and controls work remains the company’s immediate priority. GMP manufacturing of clinical-trial material is underway, and Relmada expects to file a U.S. IND by the end of 2026. Clinical sites are engaged and are expected to begin enrolling patients in the Phase 3 RESCUE registrational program after IND clearance.

For sepranolone, formulation development is complete. Finalizing the pre-filled syringe delivery system is the remaining step identified before the planned year-end 2026 IND submission. Relmada intends to begin a Phase 2 proof-of-concept study in Prader-Willi Syndrome after regulatory clearance.

The quarter’s update was therefore centered on manufacturing and regulatory preparation rather than new clinical efficacy results.

Profitability, cash flow and the balance sheet

The decline in G&A expense reflected lower stock-based compensation and employee compensation, partly offset by higher stock appreciation rights expense and consulting costs. However, the $5.6 million increase in R&D expense drove total operating expenses higher and widened the operating loss.

Cash, cash equivalents and short-term investments increased to $217.7 million at June 30, 2026, from approximately $93.0 million at December 31, 2025. The increase was funded principally through financing: Relmada reported $150.2 million of net cash provided by financing activities during the first half of 2026, while operating activities used $24.7 million.

The company also recorded $117.6 million of first-half investing outflow, largely reflecting purchases of short-term investments. That amount represents the allocation of funds into investments rather than operating expenditure.

A narrower per-share loss masks a wider net loss

Although the reported loss per share narrowed from $0.30 to $0.11, underlying losses did not improve. Net loss increased from $9.9 million to $12.9 million, while the weighted-average share count rose from 33.2 million to 112.4 million.

Relmada issued approximately 29.5 million common shares during the first half of 2026 and received $150.4 million in net proceeds. Common shares outstanding increased from 73.3 million at the end of 2025 to 106.7 million at June 30, 2026. The larger per-share denominator explains why the loss per share narrowed even as the absolute net loss widened.

Guidance and milestones

Relmada expects its current cash, cash equivalents and short-term investments to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program. The timing of both clinical programs remains dependent on completing manufacturing work and obtaining IND clearance.

Recent insider transactions

The supplied insider dataset reports no purchases or sales during the latest six-month period and total insider holdings of approximately 330,780 shares. Its ten latest records from the preceding two years were all reported as direct purchases; the transaction values below are shown as reported and do not establish insiders’ current views.

Risks investors need to watch

• Manufacturing and CMC execution: Delays in manufacturing clinical-trial material, completing the sepranolone delivery system or obtaining regulatory acceptance could push back both IND filings and subsequent trial starts.
• Clinical and regulatory uncertainty: NDV-01 and sepranolone remain investigational. Future studies may not produce sufficient efficacy or safety evidence to support registration or approval.
• Higher development spending: Quarterly R&D expense and operating cash outflow increased as the programs advanced. Further clinical development could continue to raise operating costs.
• Cash-runway uncertainty: The through-2029 estimate depends on assumptions about trial timing, manufacturing expenses and other future costs.
• Share dilution: Equity financing strengthened the balance sheet but materially expanded the share count, affecting per-share financial results.

Summary

Relmada’s Q2 2026 results reflected increased investment in manufacturing and clinical preparation for NDV-01 and sepranolone, which widened the company’s net loss and operating cash outflow. The strengthened balance sheet provides management with an expected runway through 2029, but the next major tests are completing both IND submissions, obtaining clearance and starting the planned Phase 3 and Phase 2 studies on schedule.